Visual function in chronic Leber’s hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset

Abstract

Purpose Leber's hereditary optic neuropathy (LHON) is a mitochondrial disease characterized by a subacute and progressive impairment and subsequent degeneration of retinal ganglion cells (RGCs). In most cases, it results in optic nerve atrophy and permanently reduced visual acuity (VA). Idebenone has recently been approved in Europe for treating LHON. However, published clinical data has only focused on efficacy in patients within the first years after disease onset. The present study is the first to evaluate possible effects of idebenone treatment in patients with LHON when initiated after more than 5 years from disease onset. Methods Oral treatment with idebenone 300 mg tid was started in seven patients 5 to 51 years after LHON onset. All patients had genetically confirmed primary LHON mutations (m11778G>A, m14484T>C, and m13051G>A). Visual function of all fourteen eyes was tested every 3 months using logarithmic reading charts and automated static threshold perimetry. The obtained clinical data were analyzed retrospectively using a multivariate analysis for VA and the Wilcoxon signed-rank test for visual field data. Results Before treatment, VA was 0.78 ± 0.38 logMAR (range 0.24 to 1.50 logMAR). During the first year of therapy, VA improved significantly by an average of − 0.20 ± 0.10 logMAR or 10 ± 5 ETDRS letters (P = 0.002; VA range 0.06 to 1.30 logMAR). Seven of fourteen eyes showed an improvement of 2 or more lines. Visual field mean deviation increased from − 8.02 ± 6.11 to − 6.48 ± 5.26 dB after 12 months, but this change was not statistically significant (P = 0.056). Conclusions The increase in VA of patients who have had LHON for more than 5 years observed soon after start of treatment may not constitute a coincidental spontaneous recovery. We hypothesize that the treatment response in chronic LHON was the result of a reactivated signal transduction in surviving dysfunctional RGCs. The results of this study indicate a beneficial effect of idebenone on improvement of visual function in LHON patients with established optic atrophy.Open Access This article is distributed under the terms of the Creative Comm ons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Cannabidiol modulation of oxidative stress and signalling

“…While some studies suggest that oxidative stress plays a critical role in the progression of diseases including cancer, diabetes and CNS disorders [1][2][3][4][5]74], many studies have failed to demonstrate that the therapeutic effects of antioxidants translate to a clinical setting [75]. Indeed, although antioxidants are believed to wield anti-inflammatory effects, their assessment as therapeutics in both human and rodent studies has provided contradictory findings [76][77][78][79]. On the contrary, the use of pro-oxidant molecules, such as phytol (NOX2 activator and vitamin E precursor), can improve, or even prevent, ongoing inflammation in animal models [80].…”

Diabetic Retinopathy: The Role of Mitochondria in the Neural Retina and Microvascular Disease

“…Its mitochondrial protective effects have recently been investigated as a drug therapy for Leber’s hereditary optic neuropathy, a rare genetic mitochondrial disease that causes rapid and progressive bilateral vision loss in young adults. A 24-week multi-center double-blind, randomized, placebo-controlled trial in patients with Leber’s hereditary optic neuropathy show a mild benefit in visual acuity [ 216 ] that was confirmed when treatment started 5 years after the diagnosis [ 217 ]. The benefic outcomes are considered a result of idebenone to restore the bioenergetics in the remaining dysfunctional RGC.…”

Leber’s hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation

“…These characteristics were not valid in our small patient cohort. Another publication showing a possible improvement under idebenone treatment was contributed by Pemp et al [11]: Idebenone treatment over 1 year led to an increase in VA by an average of − 0.2 logMAR in patients who had been symptomatic for 5 years or longer. It remains unclear whether a longer duration of the study would have led to further improvement or whether the long time since the onset of the disease prevented stronger improvement.…”